End-stage heart failure secondary to low-dose hydroxychloroquine treatment

Eur Heart J. 2021 Jan 7;42(2):207. doi: 10.1093/eurheartj/ehaa595.

Authors

Stefano Figliozzi¹, Stefania Rizzo², Monica De Gaspari², Giuseppe Tarantini¹

Affiliations

¹ Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, 35128 Padua, Italy.
² Cardiovascular Pathology Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health,University of Padua Medical School Via A. Gabelli, 61 35121 Padua, Italy.

PMID: 32725108
DOI: 10.1093/eurheartj/ehaa595

No abstract available

MeSH terms

COVID-19*
Heart Failure* / chemically induced
Heart Failure* / drug therapy
Humans
Hydroxychloroquine / adverse effects

Substances

Hydroxychloroquine